Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GKOS Glaukos	$101.22 +1.9%	$94.53	$77.10 ▼ $163.71	$5.67B	0.8	733,939 shs	453,393 shs
IRTC iRhythm Technologies	$152.69 +0.8%	$135.32	$55.92 ▼ $154.51	$4.84B	1.4	481,642 shs	242,343 shs
NVCR NovoCure	$17.10 -1.3%	$17.61	$14.17 ▼ $34.13	$1.93B	0.74	1.19 million shs	815,261 shs
STVN Stevanato Group	€25.24 0.0%	€22.97	€16.85 ▼ €25.88	$7.64B	0.53	339,405 shs	417,400 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GKOS Glaukos	+1.81%	-1.07%	+4.29%	-0.73%	-13.24%
IRTC iRhythm Technologies	+0.81%	+4.92%	+4.32%	+45.42%	+48.46%
NVCR NovoCure	-1.33%	+1.79%	-10.84%	-9.33%	-5.84%
STVN Stevanato Group	-0.28%	+6.59%	+10.46%	+24.64%	+47.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GKOS Glaukos	4.3867 of 5 stars	4.4	2.0	0.0	4.4	1.9	1.7	0.6
IRTC iRhythm Technologies	1.4499 of 5 stars	2.5	3.0	0.0	0.0	2.2	0.8	0.6
NVCR NovoCure	4.3261 of 5 stars	3.3	4.0	0.0	4.5	3.8	1.7	0.0
STVN Stevanato Group	2.103 of 5 stars	0.0	4.0	0.8	0.0	3.2	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GKOS Glaukos	2.75	Moderate Buy	$134.67	33.05% Upside
IRTC iRhythm Technologies	2.90	Moderate Buy	$138.60	-9.23% Downside
NVCR NovoCure	2.67	Moderate Buy	$32.83	92.01% Upside
STVN Stevanato Group	2.86	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVCR, STVN, GKOS, and IRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	IRTC iRhythm Technologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $160.00
5/22/2025	IRTC iRhythm Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$130.00 ➝ $167.00
5/6/2025	GKOS Glaukos	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$110.00 ➝ $72.00
5/2/2025	GKOS Glaukos	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$140.00 ➝ $115.00
5/2/2025	IRTC iRhythm Technologies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$152.00 ➝ $139.00
5/2/2025	IRTC iRhythm Technologies	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$133.00 ➝ $150.00
5/2/2025	IRTC iRhythm Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$104.00 ➝ $130.00
5/2/2025	IRTC iRhythm Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$138.00 ➝ $151.00
5/1/2025	GKOS Glaukos	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$140.00 ➝ $135.00
5/1/2025	GKOS Glaukos	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$140.00 ➝ $115.00
5/1/2025	GKOS Glaukos	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$176.00 ➝ $115.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GKOS Glaukos	$383.48M	15.08	N/A	N/A	$13.91 per share	7.28
IRTC iRhythm Technologies	$591.84M	8.24	N/A	N/A	$2.90 per share	52.65
NVCR NovoCure	$605.22M	3.15	N/A	N/A	$3.33 per share	5.14
STVN Stevanato Group	$1.19B	6.40	€0.75 per share	33.45	€5.02 per share	5.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GKOS Glaukos	-$146.37M	-$2.37	N/A	N/A	N/A	-31.40%	-10.66%	-8.06%	7/30/2025 (Estimated)
IRTC iRhythm Technologies	-$113.29M	-$3.14	N/A	N/A	N/A	-15.90%	-101.04%	-9.55%	7/30/2025 (Estimated)
NVCR NovoCure	-$168.63M	-$1.51	N/A	N/A	N/A	-26.41%	-45.46%	-13.34%	7/24/2025 (Estimated)
STVN Stevanato Group	$127.45M	€0.51	49.49	43.52	2.41	11.14%	10.00%	6.03%	N/A

Latest NVCR, STVN, GKOS, and IRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	NVCR NovoCure	-$0.40	N/A	N/A	N/A	$153.87 million	N/A
5/1/2025	Q1 2025	IRTC iRhythm Technologies	-$0.89	-$0.95	-$0.06	-$0.97	$153.39 million	$158.68 million
4/30/2025	Q1 2025	GKOS Glaukos	-$0.33	-$0.22	+$0.11	-$0.32	$102.78 million	$106.66 million
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GKOS Glaukos	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A
STVN Stevanato Group	N/A	N/A	N/A	N/A	1 Years

Latest NVCR, STVN, GKOS, and IRTC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	STVN Stevanato Group	annual	€0.06	0.3%	6/5/2025	6/5/2025	7/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GKOS Glaukos	0.09	6.49	5.62
IRTC iRhythm Technologies	7.47	5.71	5.58
NVCR NovoCure	0.27	1.47	1.41
STVN Stevanato Group	0.22	1.83	1.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GKOS Glaukos	99.04%
IRTC iRhythm Technologies	N/A
NVCR NovoCure	84.61%
STVN Stevanato Group	N/A

Insider Ownership

Company	Insider Ownership
GKOS Glaukos	5.80%
IRTC iRhythm Technologies	1.10%
NVCR NovoCure	5.52%
STVN Stevanato Group	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GKOS Glaukos	780	57.14 million	53.83 million	Optionable
IRTC iRhythm Technologies	2,000	31.92 million	31.57 million	Optionable
NVCR NovoCure	1,488	111.49 million	105.33 million	Optionable
STVN Stevanato Group	5,521	302.84 million	300.72 million	Optionable

NVCR, STVN, GKOS, and IRTC Headlines

Recent News About These Companies

Stevanato Group (NYSE:STVN) Sets New 1-Year High - What's Next?

June 26 at 4:21 PM | marketbeat.com

Stevanato Group S.P.A. (IT0005452658.SG)

June 26 at 1:46 PM | sg.finance.yahoo.com

Cooper Investors PTY Ltd. Buys 25,221 Shares of Stevanato Group S.p.A. (NYSE:STVN)

June 24 at 5:47 AM | marketbeat.com

Stevanato: Recovery Underway, Buy Confirmed

June 22, 2025 | seekingalpha.com

Stevanato Group S.p.A. (NYSE:STVN) Shares Sold by Riverbridge Partners LLC

June 20, 2025 | marketbeat.com

USNA vs. STVN: Which Stock Is the Better Value Option?

June 18, 2025 | zacks.com

Conestoga Capital Advisors LLC Raises Position in Stevanato Group S.p.A. (NYSE:STVN)

June 17, 2025 | marketbeat.com

Stevanato Group (NYSE:STVN) Shares Down 4.7% - Here's What Happened

June 12, 2025 | marketbeat.com

Subcontractor sues for nearly $1.6M in unpaid work on Stevanato site in Fishers

June 12, 2025 | theindianalawyer.comT

Yarbrough Capital LLC Acquires Shares of 16,113 Stevanato Group S.p.A. (NYSE:STVN)

June 8, 2025 | marketbeat.com

Stevanato Group S.p.A. (NYSE:STVN) Receives Average Recommendation of "Moderate Buy" from Analysts

June 6, 2025 | marketbeat.com

Stevanato Group S.p.A. (NYSE:STVN) Short Interest Update

June 5, 2025 | marketbeat.com

Ex-Dividend Reminder: Stevanato Group SpA, Golden Ocean Group and Flowers Foods

June 4, 2025 | nasdaq.com

Wellington Management Group LLP Trims Position in Stevanato Group S.p.A. (NYSE:STVN)

June 4, 2025 | marketbeat.com

GRFS vs. STVN: Which Stock Is the Better Value Option?

June 2, 2025 | zacks.com

Stevanato Group S.p.A. (STVN): A Bull Case Theory

May 30, 2025 | msn.com

D. E. Shaw & Co. Inc. Takes Position in Stevanato Group S.p.A. (NYSE:STVN)

May 29, 2025 | marketbeat.com

Bank of America Corp DE Sells 77,677 Shares of Stevanato Group S.p.A. (NYSE:STVN)

May 29, 2025 | marketbeat.com

Northern Trust Corp Decreases Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

May 28, 2025 | marketbeat.com

Stevanato Group S.p.A. (STVN) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Stevanato Group to Participate in Upcoming Investor Conferences

May 9, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCR, STVN, GKOS, and IRTC Company Descriptions

Glaukos NYSE:GKOS

$101.22 +1.91 (+1.92%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$101.11 -0.11 (-0.11%)

As of 06/26/2025 07:56 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

iRhythm Technologies NASDAQ:IRTC

$152.69 +1.22 (+0.81%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$148.37 -4.32 (-2.83%)

As of 06/26/2025 04:11 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

NovoCure NASDAQ:NVCR

$17.10 -0.23 (-1.33%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$17.09 -0.01 (-0.06%)

As of 06/26/2025 06:27 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Stevanato Group NYSE:STVN

€25.24 -0.01 (-0.04%)

As of 06/26/2025 03:58 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time